<DOC>
	<DOCNO>NCT01336478</DOCNO>
	<brief_summary>The investigator propose nonrandomized , Phase I study assess safety infusion NK cell select sibling donor infuse patient hematological malignancy early follow allogeneic stem cell transplantation .</brief_summary>
	<brief_title>CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( HSCT ) effective treatment number hematological malignancy relapse remain major problem , especially patient high risk disease . Natural killer ( NK ) cell immune cell recognize kill virally infected cell tumor cell . NK cell identify expression CD56 surface antigen lack CD3 . Their ability kill tumor cell make promise evaluate effector cell immunotherapy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>1 . Patients undergo allogeneic HSCT sibling donor , treatment hematological malignancy . The condition regimen , particular whether ablative non ablative , consider criterion recruitment 2 . Patient donor Age &gt; 18 year 3 . Patients donor must sign informed consent form 4 . The donor must willing capable donating lymphocyte NK selection use apheresis technique 5 . Donor must fit undergo leukapheresis 1 . Life expectancy &lt; 3 month 2 . ECOG performance status 3 4 3 . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , life threaten cardiac arrhythmia 4 . Patients eligible receive vivo T depletion ATG , ALG campath1H 5 . HIVpositive patient 6 . Psychiatric illness/social situation would limit compliance study requirement ability comprehend investigational nature study provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>NK</keyword>
	<keyword>natural killer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>leukemia</keyword>
	<keyword>hematological malignancy</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>adoptive therapy</keyword>
</DOC>